Vascular complications in transfemoral TAVI are relatively frequent. VARC major vascular complications increase 30-day mortality and are predicted by experience, femoral calcification, and SFAR. Routine application of SFAR will improve patient selection for transfemoral TAVI and may improve outcome.

Experience reduced major vascular complications in a true percutaneous approach for transfemoral-TAVI. Further application of this less invasive strategy is feasible and may be beneficial, in this high-risk patient cohort.

Better endograft-stent apposition was achieved when using 30% endograft oversizing. Lower stent compression, but wider gutters, were observed with the Excluder stent-graft and V12 parallel stent, achieving maximum stent compression with the Endurant-Viabahn combination.

Thirty-two patients with adrenal adenocarcinoma are reviewed. Eleven of them had symptoms suggestive of a hormonally functional tumor. The median survival in 17 patients who had the primary tumor removed was 13.5 months from the time of surgery, with one patient surviving disease-free 19 years later. The median survival of 11 patients who did not have surgery owing to delays in diagnosis was 7.5 months from the onset of symptoms. Of six patients given O,P'DDD, two patients had objective regression, one partial, one complete. Early diagnosis may improve survival and curability of this malignant tumor.

No abstract